Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Sematilide is a class III antiarrhythmic agent and an analog of sotalol (Item No. 16136).1 It prolongs electrically stimulated action potential duration (APD) and increases the effective refractory period (ERP) in isolated guinea pig left atria. Sematilide decreases spontaneous sinoatrial beating rates and induces ERP prolongation of the atrioventricular node in isolated perfused canine hearts.2 In situ, sematilide (1 mg/kg) increases ERP, prolonging cardiac refractoriness, in open-chest dog hearts. Sematilide (0.3-6 mg/kg) inhibits arrhythmias induced by programmed electrical stimulation (PES), but not coronary ligation and reperfusion, two-stage coronary ligation, adrenaline, or digitalis, in dogs.3 Formulations containing sematilide have been used in the treatment of arrhythmias.
WARNING This product is not for human or veterinary use.
1. Effects of sematilide, a novel class III antiarrhythmic agent, on action potential in guinea pig atrium. Jpn. J. Pharmacol. 68(2), 175-182 (1995).
2. Comparison of direct negative chronotropic and positive inotropic effects of sematilide to those of E-
3. Antiarrhythmic and proarrhythmic effects of sematilide in canine ventricular arrhythmia models. Jpn. J. Pharmacol. 70(2), 129-138 (1996).